Clinical Trial

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

Study acronym: OPTION-DDR
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The usual approach for most patients who are not in a study is treatment with docetaxel. This study is being done to answer the following question: Can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual approach? This study is being done to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach is defined as the care most people get for prostate cancer.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2024-05-27; most recent amendment 2026-04-15.
Status change: Not Yet Recruiting → Recruiting 2024-12-23
Trial Details
NCT Number NCT06439225
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Canadian Institutes of Health Research (CIHR)
Conditions Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Enrollment 236 participants
Start Date 2024-12-30
Primary Completion 2029-09-30 (estimated)
Study Completion 2030-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-16